Skip to content
Clinical Trials – home

Mesalazine: A Comprehensive Guide for Patients

1 / 2
trials open to patients / all trials
3+
Countries

In short

Mesalazine, also known as 5-aminosalicylic acid (5-ASA), is a medication widely studied in clinical trials for its effectiveness in treating inflammatory bowel diseases, particularly ulcerative colitis. This article explores various clinical trials investigating the use of mesalazine in different formulations and dosing regimens, as well as its potential benefits in managing symptoms, inducing remission, and improving quality of life for patients with these conditions.

At a glance

Primary Uses
Treatment of ulcerative colitis, maintenance of remission
Formulations
Tablets (e.g., Asacol, Pentasa, Lialda), various dosages
Dosing Regimens
Once daily (e.g., 1600 mg, 2.4 g) or multiple daily doses
Key Outcomes Measured
Clinical remission, endoscopic remission, quality of life, disease activity scores
Safety Assessments
Adverse events, laboratory results, vital signs, physical examination findings
Additional Research Areas
Potential use in reducing immune activation in HIV patients

What is Mesalazine?

Mesalazine, also known as 5-aminosalicylic acid (5-ASA), is a medication primarily used to treat inflammatory bowel diseases. It belongs to a class of drugs called aminosalicylates. Mesalazine is marketed under various brand names, including Asacol, Pentasa, and Lialda.

What Conditions Does Mesalazine Treat?

Mesalazine is primarily used to treat the following conditions:

  • Ulcerative Colitis (UC): This is a type of inflammatory bowel disease that causes inflammation and ulcers in the colon and rectum. Mesalazine is used for both inducing and maintaining remission in patients with mild to moderate UC.
  • Distal Ulcerative Colitis: This refers to inflammation limited to the lower part of the colon, including conditions like proctitis (inflammation of the rectum) and proctosigmoiditis (inflammation of the rectum and sigmoid colon).
  • Crohn's Disease: Although not explicitly mentioned in the provided trials, mesalazine is sometimes used in the treatment of Crohn's disease, another type of inflammatory bowel disease.

How Does Mesalazine Work?

Mesalazine works by reducing inflammation in the intestines. While the exact mechanism is not fully understood, it is believed to work locally in the gut to decrease the production of chemicals that cause inflammation, such as prostaglandins and leukotrienes.

Interestingly, some research suggests that mesalazine may have additional beneficial effects. For example, one study is investigating whether mesalazine can induce the expression of certain genes (like μ-protocadherin) in the colon mucosa, which might help prevent colorectal cancer.

Dosage Forms and Administration

Mesalazine is available in various forms and dosages, including:

  • Tablets: These come in different strengths, such as 400 mg, 800 mg, and 1.2 g.
  • Extended-release tablets: These are designed to release the medication slowly throughout the digestive tract.
  • Suppositories and enemas: These forms are used for treating inflammation in the lower part of the colon and rectum.

The dosing regimen can vary depending on the specific condition being treated, the severity of the disease, and the individual patient. For example:

  • For maintaining remission in ulcerative colitis, a common dosage is 2.4 g per day, which can be taken as a single daily dose or divided into multiple doses.
  • For active mild to moderate ulcerative colitis, higher doses may be used for inducing remission.

Effectiveness of Mesalazine

Mesalazine has been shown to be effective in treating ulcerative colitis and maintaining remission. Clinical trials have evaluated its effectiveness using various measures:

  • Clinical remission: This is often measured using scoring systems like the Mayo Score or the Simple Clinical Colitis Activity Index (SCCAI).
  • Endoscopic remission: This involves examining the lining of the colon using a camera (endoscopy) to assess healing.
  • Histological remission: This involves examining tissue samples under a microscope to assess inflammation at a cellular level.
  • Quality of life: Some studies have looked at how mesalazine treatment affects patients' overall well-being and daily functioning.

Potential Side Effects

While mesalazine is generally well-tolerated, like all medications, it can cause side effects. Common side effects may include:

  • Headache
  • Nausea
  • Abdominal pain
  • Diarrhea

More serious side effects are rare but can include allergic reactions, kidney problems, or liver problems. It's important to discuss any side effects with your healthcare provider.

Ongoing Research and Future Prospects

Research on mesalazine is ongoing, with studies exploring various aspects of its use:

  • Dosing regimens: Studies are comparing different dosing schedules (e.g., once daily vs. multiple times daily) to optimize effectiveness and patient adherence.
  • Long-term effects: Researchers are investigating the long-term safety and effectiveness of mesalazine in maintaining remission.
  • Cancer prevention: Some studies are exploring whether mesalazine might help prevent colorectal cancer in patients with ulcerative colitis.
  • Other conditions: Interestingly, one study is investigating whether mesalazine might help reduce immune activation in HIV patients, potentially offering benefits beyond its traditional use in inflammatory bowel diseases.

As research continues, our understanding of mesalazine and its potential uses may expand, potentially leading to improved treatments for patients with inflammatory bowel diseases and possibly other conditions.

Questions people often ask

Conditions where Mesalazine is being studied

Each condition opens its own overview and trial list

Trials with Mesalazine

Recruiting trials first

See all 2 →
Quick filters
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).